Teclistamab in Relapsed or Refractory Multiple Myeloma (MajesTEC-1)
Source: View publication →
In heavily pretreated patients with relapsed or refractory multiple myeloma, the off-the-shelf BCMAxCD3 bispecific antibody teclistamab yielded a 63.0% overall response rate with deep and durable remissions, despite high rates of cytopenias and infections.
Key Findings
Study Design
Study Limitations
Clinical Significance
The MajesTEC-1 trial established teclistamab as a highly active, first-in-class T-cell redirecting bispecific antibody for multiple myeloma. By achieving a 63.0% response rate in patients with a median of five prior lines of therapy (and 77.6% with triple-class refractory disease), teclistamab provided an immediately accessible ('off-the-shelf') alternative to CAR-T cell therapies. This pivotal data led to its accelerated FDA approval in late 2022, fundamentally shifting the treatment paradigm for highly refractory multiple myeloma and establishing BCMA-targeted bispecifics as a new pillar of care.
Historical Context
Multiple myeloma remains an incurable plasma cell malignancy. Prior to the advent of BCMA-directed therapies, patients who became refractory to the three main classes of anti-myeloma agents—proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies—faced a dismal prognosis, with historical median overall survival of less than a year. While BCMA-directed CAR-T cell therapies (idecabtagene vicleucel and ciltacabtagene autoleucel) demonstrated unprecedented efficacy in this population, they are constrained by complex logistics, apheresis requirements, and multi-week manufacturing delays. Teclistamab was developed to bypass these logistical hurdles by bridging T cells directly to myeloma cells in vivo via an off-the-shelf injection. The MajesTEC-1 study was a landmark moment, proving that a bispecific antibody could achieve CAR-T-like response rates and durations, democratizing access to powerful T-cell redirecting therapies for multiple myeloma patients.
Guided Discussion
High-yield insights from every perspective
Teclistamab is a BCMAxCD3 bispecific antibody. What is the physiological role of BCMA in plasma cell biology, and how does engaging CD3 mediate tumor cell death in this context?
Key Response
BCMA (B-cell maturation antigen) is a receptor heavily expressed on plasma cells that promotes their survival and proliferation by binding to BAFF and APRIL. Engaging CD3 on T-cells brings them into close proximity with BCMA-expressing myeloma cells, inducing T-cell activation, proliferation, and perforin/granzyme-mediated apoptosis of the tumor cells independent of MHC restriction.
Given the high rates of cytokine release syndrome (CRS) and infections seen in the MajesTEC-1 trial, what are the initial management steps for a patient presenting with fever and hypotension shortly after step-up dosing of teclistamab?
Key Response
Fever and hypotension post-dosing indicate Grade 2 or higher CRS, but sepsis must be simultaneously ruled out. Initial management requires drawing blood cultures and starting broad-spectrum antibiotics, while concurrently treating the CRS with the IL-6 receptor antagonist tocilizumab, IV fluids, and potentially corticosteroids and vasopressors if refractory.
For a triple-class refractory myeloma patient, how do you decide between recommending a BCMA-directed CAR-T cell therapy versus an off-the-shelf BCMA bispecific like teclistamab, considering the efficacy, toxicity profile, and logistical constraints highlighted in MajesTEC-1?
Key Response
CAR-T offers a 'one-and-done' treatment with potentially deeper remissions but has high manufacturing wait times, risk of disease progression during bridging, and severe CRS/ICANS. Teclistamab is immediately available ('off-the-shelf') and highly effective for rapidly progressing disease, but requires continuous dosing and carries a sustained risk of severe infections and hypogammaglobulinemia.
The MajesTEC-1 trial reported high rates of severe, sometimes fatal, opportunistic infections and hypogammaglobulinemia. As continuous teclistamab therapy becomes integrated into our practice, how should we systematically adapt our prophylactic strategies to mitigate this chronic infectious risk?
Key Response
Continuous T-cell redirection and B-cell depletion lead to profound, lasting immune suppression. Attending physicians must proactively implement IVIG replacement for hypogammaglobulinemia, along with rigorous antimicrobial prophylaxis (e.g., PJP, HSV/VZV, and possibly antibacterial/antifungal cover) and ensure vaccination optimization prior to therapy initiation.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
MajesTEC-1 is a phase 1/2 single-arm study. In heavily pretreated populations, how can researchers methodologically establish robust synthetic control arms or utilize real-world data (RWD) to contextualize the 63 percent ORR, avoiding the biases inherent in historical cross-trial comparisons?
Key Response
Researchers can use techniques like propensity score matching or inverse probability of treatment weighting (IPTW) on prospective observational registries (like the LocoMMotion cohort) to match baseline characteristics. Critiquing single-arm designs requires addressing unmeasured confounding, selection bias, and temporal shifts in standards of care.
When reviewing the progression-free survival (PFS) and duration of response (DOR) curves in this single-arm study, what specific aspects of patient censoring and early dropouts (e.g., due to COVID-19 or toxicity) would a peer reviewer flag as potential threats to the validity of the survival estimates?
Key Response
High early dropout rates or informative censoring (e.g., dropping out due to adverse events like infections rather than random loss to follow-up) can artificially inflate Kaplan-Meier estimates for PFS and DOR. Editors must demand sensitivity analyses that treat toxicity-related dropouts as events to ensure the efficacy isn't overstated.
Based on the MajesTEC-1 data, teclistamab received accelerated approval. How should guideline committees position teclistamab within current algorithms for RRMM relative to existing options, and what evidentiary gaps must be filled before assigning it a Category 1 recommendation?
Key Response
Current guidelines recommend teclistamab for patients with 4 or more prior lines including an IMiD, PI, and anti-CD38 mAb. To upgrade to a Category 1 recommendation, committees require Phase 3 randomized controlled trial data comparing teclistamab directly to standard-of-care regimens, specifically evaluating overall survival, patient-reported outcomes, and long-term cumulative toxicity.
Clinical Landscape
Noteworthy Related Trials
KarMMa Trial
Tested
Idecabtagene vicleucel (ide-cel)
Population
Triple-class exposed relapsed/refractory multiple myeloma
Comparator
None (single-arm)
Endpoint
Overall Response Rate (ORR)
CARTITUDE-1 Trial
Tested
Ciltacabtagene autoleucel (cilta-cel)
Population
Triple-class exposed relapsed/refractory multiple myeloma
Comparator
None (single-arm)
Endpoint
Overall Response Rate (ORR)
MagnetisMM-3 Trial
Tested
Elranatamab
Population
BCMA-naive relapsed/refractory multiple myeloma
Comparator
None (single-arm)
Endpoint
Overall Response Rate (ORR)
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis